Please Enable Cookies

www.laserfocusworld.com is using a security service for protection against online attacks. This process is automatic. You will be redirected once the validation process is complete.

Recent Quotes
My Watchlist
Indicators
Industrial Laser Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Karyopharm Therapeut (NQ: KPTI )

0.8112 -0.0288 (-3.43%)
Streaming Delayed Price Updated: 4:00 PM EDT, Aug 7, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,031,680
Open 0.8500
Bid (Size) 0.7912 (13)
Ask (Size) 0.8850 (2)
Prev. Close 0.8400
Today's Range 0.7900 - 0.9000
52wk Range 0.6174 - 1.950
Shares Outstanding 114,010,448
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Karyopharm Therapeutics (KPTI) Q2 2024 Earnings Call Transcript
KPTI earnings call for the period ending June 30, 2024. 
Via The Motley Fool
Topics Earnings
Exposures Financial
KPTI Stock Earnings: Karyopharm Therapeutics Beats EPS, Beats Revenue for Q2 2024
KPTI stock results show that Karyopharm Therapeutics beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024. 
Via InvestorPlace

Performance

YTD
-9.99%
-9.99%
1 Month
+2.67%
+2.67%
3 Month
-26.25%
-26.25%
6 Month
-51.13%
-51.13%
1 Year
-49.61%
-49.61%

More News

Read More
The Next Novavax? 3 Biopharma Stocks to Buy Before They Boom
Via InvestorPlace
Karyopharm Therapeutics (KPTI) Q1 2024 Earnings Call Transcript
Via The Motley Fool
Topics Earnings
Exposures Financial
KPTI Stock Earnings: Karyopharm Therapeutics Beats EPS, Misses Revenue for Q1 2024
Via InvestorPlace
Karyopharm Therapeutics (KPTI) Q4 2023 Earnings Call Transcript
Via The Motley Fool
Topics Earnings
Exposures Financial
Earnings Scheduled For February 29, 2024
Via Benzinga
Karyopharm Therapeutics's Earnings: A Preview
Via Benzinga
Earnings Preview For Karyopharm Therapeutics
Via Benzinga
6 Analysts Have This to Say About Karyopharm Therapeutics
Via Benzinga
7 Biotech Penny Stocks on the Verge of Clinical Trial Victory
Via InvestorPlace
12 Health Care Stocks Moving In Tuesday's Intraday Session
Via Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
Via Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
12 Health Care Stocks Moving In Wednesday's After-Market Session
Via Benzinga
Karyopharm Therapeutics (KPTI) Q3 2023 Earnings Call Transcript
Via The Motley Fool
Topics Earnings
Exposures Financial
Stocks That Hit 52-Week Lows On Wednesday
Via Benzinga
Karyopharm Therapeutics (KPTI) Q2 2023 Earnings Call Transcript
Via The Motley Fool
Karyopharm's Selinexor Shows Progression-Free Survival of 27.4 Months In Endometrial Cancer With Certain Mutation
Via Benzinga
Stocks That Hit 52-Week Lows On Tuesday
Via Benzinga
CMG Stock Alert: Chipotle Announces International Expansion Plan
Via InvestorPlace
Why Are Karyopharm Therapeutics Shares Gaining Today?
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
Why Is CEL-SCI (CVM) Stock Down 23% Today?
Via InvestorPlace
Why Is Masimo (MASI) Stock Down 30% Today?
Via InvestorPlace
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.